Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Daan Gene Co. Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single case is being reviewed by 1 distinct examiner in 1 distinct art unit. This prosecution profile suggests that the company is focusing its immediate resources on a specific technical filing rather than a broad array of applications.
JULIET CAROLINE SWITZER is the busiest examiner for this entity, currently managing 1 busiest examiner pending action. Because she is the only examiner assigned to the company's pending work, the success of the current strategy depends on the interaction with her. The 1 distinct art unit involved indicates a narrow technical classification for the pending Biotechnology & Pharmaceuticals claims.
With only 1 pending office action, the administrative requirements are focused on a single response cycle. This allows for a highly targeted approach to the examiner's specific concerns. The data shows that this active case is the only matter currently requiring the attention of the company's legal representatives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713016 | REVERSE-TRANSCRIPTION AMPLIFICATION SYSTEM AND METHOD BASED ON RECOMBINASE POLYMERASE AMPLIFICATION TECHNOLOGY | SWITZER, JULIET CAROLINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713016 | REVERSE-TRANSCRIPTION AMPLIFICATION SYSTEM AND METHOD BASED ON RECOMBINASE POLYMERASE AMPLIFICATION TECHNOLOGY | SWITZER, JULIET CAROLINE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713016 | REVERSE-TRANSCRIPTION AMPLIFICATION SYSTEM AND METHOD BASED ON RECOMBINASE POLYMERASE AMPLIFICATION TECHNOLOGY | SWITZER, JULIET CAROLINE | 1682 | §101§102§112DP | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDaan Gene Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Juliet Caroline Switzer has the most, with 1 of Daan Gene Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
